Wugen raises $172M in Series B to focus on natural killer cell therapies to treat solid tumors
July 16, 2021
Wugen, a biotech company focusing on natural killer and CAR T cell therapies, has raised $172 million in a Series B. The natural killer cells are sourced from healthy donors and are then engineered to kill cancer cells.
Wugen's lead program focuses on natural killer cell therapy for treating acute myelogenous leukemia (AML).
Want to learn more about cell therapy? Sign up our course on cell therapy!
Sign up for our Cell Therapy Course here
Text & media
The other sections are styled to help you create beautiful, high-converting pages. If you already know exactly what you want, use this section to add text, images, video, audio, etc. and build something completely custom. This is your sandbox — create what you want!